Indivior Pharmaceuticals, Inc.
NASDAQINDV is absorbing its sharpest weekly decline in months, down nearly 11% to $36.50, after the stock fell more than 8% on earnings day — a result that has sharpened the debate between those backing Sublocade's long-term growth story and those watching revenue contract in 2026. The earnings reaction is what dominates the setup this week. The stock fell 8.8% on August 3rd following…
Snapshot as of 6 Aug 2026
INDV is absorbing its sharpest weekly decline in months, down nearly 11% to $36.50, after the stock fell more than 8% on earnings day — a result that has sharpened the debate between those backing Sublocade's long-term…
Indivior Pharmaceuticals enters the late-May period with a notable gap opening up between price and short sentiment — the stock has rallied 13% over the past month while shorts are quietly trimming, creating a setup…
INDV delivered a sharp Q1 2026 earnings beat today, setting up an unusually charged week-end for a stock that shorts have been quietly building into. Q1 adjusted EPS came in at $0.96, versus a Street estimate of $0.66.…
INDV enters its April 30 earnings release with momentum firmly behind it — but short sellers are quietly building positions even as the stock climbs. The price action tells an optimistic story. INDV has gained 18% over…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for INDV — free to start on ORTEX.
Sign up for free →Open INDV on ORTEX